Search results
Earnings Roundup: DermTech, Exagen, Lucid Diagnostics, Oncocyte
GenomeWeb News· 4 days agoDermTech said this week that its first quarter revenues grew 9 percent year over year to $3.8 million from $3.5 million. Test revenues rose to $3.7 million from $3.4 million, while contract ...
Selena Gomez relieved focus on Cannes entry 'Emilia Perez,' not personal life
Reuters· 1 day agoSelena Gomez said that she was relieved focus had shifted to her role in the new Mexican cartel...
St. Louis County members want Congress to expand federal compensation for radiation exposure
AOL· 4 days agoIn the 1940s the U.S. was in a race to build the first nuclear weapons, setting up testing sites and...
What Causes Blood Clots in Lungs (Pulmonary Embolism)?
Health via Yahoo News· 3 days agoStudies show that rates of pulmonary embolism and PE mortality...
Fiction, reality converge in ‘Wildcat’ film screening | The Emory Wheel
The Emory Wheel· 3 days agoEmory University students, Atlanta cinephiles and literature lovers all waited in a sprawling line...
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Zacks via Yahoo Finance· 7 days agoAllogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and...
AstraZeneca selects new heart failure target with BenevolentAI
Pharmaceutical Technology via Yahoo Finance· 5 days agoIn January 2022, the deal was expanded to include heart failure and systemic lupus erythematosus,...
Selena Gomez explains why she disabled public Instagram comments
TODAY via Yahoo News· 6 days agoThey fuss about everything. She added: "I felt empowered by doing that, by saying, 'This is just for...
HUNDREDS OF PHYSICIANS AND MEDICAL PRACTITIONERS SET TO CONVENE AT THE 2024 ANNUAL CIRS CONFERENCE...
Coronado Eagle & Journal· 6 days agoDr. Scott McMahon of Whole World Health Care is happy to announce the 2024 annual Surviving...
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
Motley Fool via Yahoo Finance· 6 days agoIs CRISPR stock a buy? CRISPR remains on track to start clinical trials for CTX112, a gene-editing...